You can accumulate all of mine at 5c. However, you probably mean...

First 12 Last

Share
Profile

Follow
gallea

2,579 Posts.

298

02/02/16

15:39

Post #: 16923448
Share

Originally posted by Smugtown ↑

Key thoughts/points for me from the quarterly:

- WOW, shocked sales were not only lower this quarter - HEAPS lower. And sales force arrangement began in the US (a lot bigger market). I really believed we would see some good qrtly growth QoQ from here

- Some sort of explanation on why sales have gone backwards should have been provided

- In some respects i'm not as concerned about the low sales as i would have been 2-3 months ago, as the game changed for me when i learnt that we were chasing hard for a multi-national agreement

- If energies are being poured into data analytics, clinical trial, partnership agreement, best of breed device - and not on sales - because of the change of course of direction a few months ago - then i am ok with it if it expedites a multi national partnership. However there was no contact this was the case (phrase of wishful thinking springs to mind)

- the cost of the app and device is too high

- once it is subsidised it will become more popular

- I still believe the value is coming from partnering with a multi-national (so getting required clinical trial results first) - so we are on track there

- Given sales are so poor it is now more surprising to me they haven't mentioned the bits of news discovered by HC posters over the last month or two (WA subsidy and pericoach being a superior, safer alternative to the mesh). However we did get the improved sexual function news (believed to be a value inflexion point for ALT

- Likely capital raise at .04c in two months without any positive news

- Best result is options expire, we get news about clinical trial providing necessary results, news on progressive discussion on multi-national corporations, news on other states following WA's lead on subsidising product... to give the SP a boost before the CR, so we can raise between .06-.10

- I was hoping this might be a 30 bagger from here - looks like we'll have to settle for a 10-15 bagger as takeover seems most likely way now to release s/holder value

- Very happy to accumulate at 5c and up to 8c on serious positive news announcements.

Expand

You can accumulate all of mine at 5c. However, you probably mean 0.5C !!!

ALT Price at posting: 0.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 20 more messages in this thread...

First 12 Last

Add ALT (ASX) to my watchlist

You can accumulate all of mine at 5c. However, you probably mean...

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The winners & losers on market if negative gearing were gone

Featured News